ParkinsonFranceV1, PubMed, Curation, bibRecord, 000773

What can we expect from the serotonergic side of L-DOPA?

Identifieur interne : 000773 ( PubMed/Curation ); précédent : 000772; suivant : 000774

What can we expect from the serotonergic side of L-DOPA?

Auteurs : P. De Deurwaerdère [France] ; S. Navailles

Source :

Revue neurologique [ 0035-3787 ] ; 2012.

RBID : pubmed:22560009

English descriptors

KwdEn :
- Animals, Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Dyskinesia, Drug-Induced (drug therapy), Humans, Levodopa (adverse effects), Levodopa (pharmacology), Levodopa (therapeutic use), Parkinson Disease (drug therapy), Serotonergic Neurons (drug effects), Serotonergic Neurons (physiology), Serotonin (metabolism), Serotonin (physiology), Serotonin Agents, Serotonin Receptor Agonists (therapeutic use), Synaptic Transmission (drug effects).
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , metabolism : Serotonin.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , physiology : Serotonin.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa, Serotonin Receptor Agonists.
- drug effects : Serotonergic Neurons, Synaptic Transmission.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- physiology : Serotonergic Neurons.
- Animals, Humans, Serotonin Agents.

Abstract

Parkinson's disease has long been associated with neurodegeneration of the dopaminergic neurons located in the substantia nigra. The metabolic precursor L-DOPA, administered exogenously to patients, has proven its superiority over other medications. Yet, its effectiveness is altered after long-term use by diverse motor and non-motor symptoms. Knowledge of its mechanism of action would be necessary to better apprehend the side effects, but do we really know where and how it works? The connexion between L-DOPA and the serotonergic system, after a sort of crusade lasting for more than 40 years, has been acknowledged recently. The purpose of this review, mainly based on preclinical data, is to present the pharmacological and biochemical evidence demonstrating that serotonergic neurons are mainly involved in the enhancement of dopamine transmission induced by L-DOPA. We are addressing thereafter the two main expectations coming from this mechanism that are fundamental and clinical. The fundamental part will focus on the conceptual framework imposed by such a mechanism, questioning notably the notion that the benefit of L-DOPA is associated with a restoration of dopamine levels in the caudate-putamen. The clinical part will discuss serotonergic strategies to ameliorate the benefit of L-DOPA treatment in line with past and current clinical trials.

DOI: 10.1016/j.neurol.2012.01.585
PubMed: 22560009

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000809

Links to Exploration step

pubmed:22560009

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What can we expect from the serotonergic side of L-DOPA?</title>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
<affiliation wicri:level="1"><nlm:affiliation>UMR CNRS 5293, université Victor-Segalen Bordeaux-2, institut des maladies neurodégénératives, 146 rue Léo-Saignât, Bordeaux cedex, France. deurwaer@u-bordeaux2.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR CNRS 5293, université Victor-Segalen Bordeaux-2, institut des maladies neurodégénératives, 146 rue Léo-Saignât, Bordeaux cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22560009</idno>
<idno type="pmid">22560009</idno>
<idno type="doi">10.1016/j.neurol.2012.01.585</idno>
<idno type="wicri:Area/PubMed/Corpus">000809</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000809</idno>
<idno type="wicri:Area/PubMed/Curation">000773</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000773</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">What can we expect from the serotonergic side of L-DOPA?</title>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
<affiliation wicri:level="1"><nlm:affiliation>UMR CNRS 5293, université Victor-Segalen Bordeaux-2, institut des maladies neurodégénératives, 146 rue Léo-Saignât, Bordeaux cedex, France. deurwaer@u-bordeaux2.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR CNRS 5293, université Victor-Segalen Bordeaux-2, institut des maladies neurodégénératives, 146 rue Léo-Saignât, Bordeaux cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Serotonergic Neurons (drug effects)</term>
<term>Serotonergic Neurons (physiology)</term>
<term>Serotonin (metabolism)</term>
<term>Serotonin (physiology)</term>
<term>Serotonin Agents</term>
<term>Serotonin Receptor Agonists (therapeutic use)</term>
<term>Synaptic Transmission (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Serotonin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Serotonin Receptor Agonists</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Serotonergic Neurons</term>
<term>Synaptic Transmission</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Serotonergic Neurons</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Serotonin Agents</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease has long been associated with neurodegeneration of the dopaminergic neurons located in the substantia nigra. The metabolic precursor L-DOPA, administered exogenously to patients, has proven its superiority over other medications. Yet, its effectiveness is altered after long-term use by diverse motor and non-motor symptoms. Knowledge of its mechanism of action would be necessary to better apprehend the side effects, but do we really know where and how it works? The connexion between L-DOPA and the serotonergic system, after a sort of crusade lasting for more than 40 years, has been acknowledged recently. The purpose of this review, mainly based on preclinical data, is to present the pharmacological and biochemical evidence demonstrating that serotonergic neurons are mainly involved in the enhancement of dopamine transmission induced by L-DOPA. We are addressing thereafter the two main expectations coming from this mechanism that are fundamental and clinical. The fundamental part will focus on the conceptual framework imposed by such a mechanism, questioning notably the notion that the benefit of L-DOPA is associated with a restoration of dopamine levels in the caudate-putamen. The clinical part will discuss serotonergic strategies to ameliorate the benefit of L-DOPA treatment in line with past and current clinical trials.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22560009</PMID>
<DateCreated><Year>2012</Year>
<Month>12</Month>
<Day>11</Day>
</DateCreated>
<DateCompleted><Year>2013</Year>
<Month>05</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>168</Volume>
<Issue>12</Issue>
<PubDate><Year>2012</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>What can we expect from the serotonergic side of L-DOPA?</ArticleTitle>
<Pagination><MedlinePgn>927-38</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2012.01.585</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0035-3787(12)00727-8</ELocationID>
<Abstract><AbstractText>Parkinson's disease has long been associated with neurodegeneration of the dopaminergic neurons located in the substantia nigra. The metabolic precursor L-DOPA, administered exogenously to patients, has proven its superiority over other medications. Yet, its effectiveness is altered after long-term use by diverse motor and non-motor symptoms. Knowledge of its mechanism of action would be necessary to better apprehend the side effects, but do we really know where and how it works? The connexion between L-DOPA and the serotonergic system, after a sort of crusade lasting for more than 40 years, has been acknowledged recently. The purpose of this review, mainly based on preclinical data, is to present the pharmacological and biochemical evidence demonstrating that serotonergic neurons are mainly involved in the enhancement of dopamine transmission induced by L-DOPA. We are addressing thereafter the two main expectations coming from this mechanism that are fundamental and clinical. The fundamental part will focus on the conceptual framework imposed by such a mechanism, questioning notably the notion that the benefit of L-DOPA is associated with a restoration of dopamine levels in the caudate-putamen. The clinical part will discuss serotonergic strategies to ameliorate the benefit of L-DOPA treatment in line with past and current clinical trials.</AbstractText>
<CopyrightInformation>Copyright © 2012 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Deurwaerdère</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>UMR CNRS 5293, université Victor-Segalen Bordeaux-2, institut des maladies neurodégénératives, 146 rue Léo-Saignât, Bordeaux cedex, France. deurwaer@u-bordeaux2.fr</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Navailles</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>05</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018490">Serotonin Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017366">Serotonin Receptor Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>333DO1RDJY</RegistryNumber>
<NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059326" MajorTopicYN="N">Serotonergic Neurons</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018490" MajorTopicYN="Y">Serotonin Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017366" MajorTopicYN="N">Serotonin Receptor Agonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year>
<Month>12</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2012</Year>
<Month>01</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>5</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22560009</ArticleId>
<ArticleId IdType="pii">S0035-3787(12)00727-8</ArticleId>
<ArticleId IdType="doi">10.1016/j.neurol.2012.01.585</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000773 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000773 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:22560009
   |texte=   What can we expect from the serotonergic side of L-DOPA?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:22560009" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

What can we expect from the serotonergic side of L-DOPA?

What can we expect from the serotonergic side of L-DOPA?

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki